Arbutus Biopharma Corporation is a clinical-stage biopharmaceutical company developing treatments for hepatitis B and other infectious diseases. The company's lead asset, imdusiran, is a subcutaneously-delivered RNA interference therapeutic designed to suppress hepatitis B virus antigens and DNA, with clinical data showing functional cure or off-treatment response in a substantial portion of patients; the company is also developing AB-101, an oral immune-activating agent, for potential use in combination therapy to achieve hepatitis B functional cure. Revenue currently derives from settlement payments related to lipid nanoparticle patent litigation and royalty streams on licensed products using the company's LNP technology, rather than from product sales, as the company remains in clinical development with no approved therapies.